drugset
Drugs / BCMA-CD19 CAR-T therapy
last change Dec 2024 re-read 3 minutes ago

BCMA-CD19 CAR-T therapy

Cell therapy

Developed for
acquired thrombotic thrombocytopenic purpura · anti-neutrophil cytoplasmic antibody-associated vasculitis · antiphospholipid syndrome · Behcet disease · immunoglobulin G4-related sclerosing disease · myositis disease · Sjogren syndrome · systemic lupus erythematosus
+1 more · systemic sclerosis
Investigated by
Peking University People's Hospital

Trials 1

today NCT06794008 · Ph 2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06794008 Dec 2024 → Dec 2027 expected Behcet disease, Sjogren syndrome, acquired thrombotic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody-associated vasculitis +5 Peking University People's Hospital Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BCMA-CD19 CAR-T therapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT06794008 ↗
Modality Cell therapy “BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells” NCT06794008 ↗
Route Intravenous “will be administered intravenously” NCT06794008 ↗